PB

Pawankumar Babasaheb Ankalkope

Active Director Director DIN 05165919
DIN 05165919 First appointment Feb 2012 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2012
Shareholding value β€’β€’β€’β€’ Premium profile

About Pawankumar Babasaheb Ankalkope

Data last updated:

Pawankumar Babasaheb Ankalkope is a Director at Croient Pharma Private Limited (since 2012). The company operates in Pharma.

DIN 05165919
Primary Designation Director
Industry Pharma
First Appointment 14 Feb 2012
Oldest Company Age 14 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Croient Pharma Private Limited U24233MH2012PTC226900
Director14 Feb 20122012Active

Board colleagues of Pawankumar Babasaheb Ankalkope

Directorship timeline

Open interactive timeline →
Croient Pharma Private Limited
Premium access

Shareholding and investment profile for Pawankumar Babasaheb Ankalkope

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Pawankumar Babasaheb Ankalkope

Pawankumar Babasaheb Ankalkope currently holds 1 directorship: Croient Pharma Private Limited (Director, since 14 Feb 2012).

Pawankumar Babasaheb Ankalkope was first appointed on 14 Feb 2012 as Director at Croient Pharma Private Limited.

The current boards of Pawankumar Babasaheb Ankalkope's companies include Dinesh Balkrishna Sawant (Croient Pharma Private Limited), Shrikant Hambirrao Rane (Croient Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available